Caroline Seymour

Managing Editor, OncLive®
Caroline Seymour is your initial point of contact for the OncLive® podcast, OncLive On Air™. She joined the company in 2018 as an assistant editor, with expertise in video production and print/digital publication. Email: cseymour@onclive.com

Articles

Serial Clinical Response Evaluation Aids in Residual Disease Detection in ESCC

August 7th 2024

Bite-on-bite biopsies and endoscopic ultrasonography with fine needle aspiration were accurate in detecting MRD after neoadjuvant chemoradiotherapy in ESCC.

Emerging HER2+ Breast Cancer Research Uses Innovative Combinations of Standard Agents

August 6th 2024

Sara M. Tolaney, MD, MPH, discusses the HER2-positive breast cancer treatment paradigm and how standard agents may be optimized to improve outcomes.

UV1 Plus Pembrolizumab Fails to Yield Survival Benefit in Metastatic/Recurrent Head and Neck Cancer

August 5th 2024

UV1 plus pembrolizumab did not improve progression-free survival or overall survival in patients with metastatic or recurrent head and neck cancer.

FDA Requests Additional Demonstration of OS Benefit to Support Iomab-B BLA in R/R AML

August 5th 2024

The FDA is requiring an additional trial demonstrating an OS benefit with Iomab-B to support the planned filing of the biologics license application for the agent.

LP-300 Plus Chemo Yields Early Efficacy Results in Never-Smokers With NSCLC

August 5th 2024

LP-300 plus pemetrexed/carboplatin exhibited disease control in never-smokers with advanced NSCLC following progression on prior TKI treatment.

Tumor-Informed ctDNA Assay May Aid Surveillance Strategies in Merkel Cell Carcinoma

August 5th 2024

A tumor-informed ctDNA assay showed high sensitivity and specificity as well as potential for ctDNA to be used as a prognostic biomarker during surveillance in Merkel cell carcinoma.

EMA Grants Orphan Medicinal Product Designation to Rivoceranib/Camrelizumab in First-Line Unresectable HCC

August 1st 2024

The EMA has granted orphan medicinal product designation to rivoceranib plus camrelizumab in first-line unresectable hepatocellular carcinoma.

FDA Grants Fast Track Designation to Soquelitinib for Relapsed/Refractory PTCL

August 1st 2024

Soquelitinib has received fast track designation from the FDA for patients with relapsed or refractory peripheral T-cell lymphoma after at least 2 lines of systemic therapy.

IMM-1-104 Earns FDA Fast Track Designation for First-Line PDAC

August 1st 2024

The FDA granted fast track designation to IMM-1-104 for first-line pancreatic ductal adenocarcinoma.

Clinically Guided Cannabis Use Helps Mitigate Symptoms Experienced by Patients With Cancer

August 1st 2024

Blake Zenger, MBA, and Brooke Worster, MD, MS, FACP, highlight the importance of personalized cannabis use in alleviating treatment-related symptoms.

Evorpacept Plus TRP Yields Durable Responses in HER2+ Gastric/GEJ Cancer

July 31st 2024

Evorpacept plus TRP generated clinically meaningful, robust, and durable responses in patients with previously treated HER2-positive gastric or GEJ cancer.

Model Validates Cost Savings With Cannabis in Mitigating Symptoms for Patients With Cancer

July 31st 2024

Blake Zenger, MBA, and Brooke Worster, MD, MS, FACP, detail a health care cost impacts model pertaining to the use of cannabis for therapy-related symptoms

FDA Grants Rare Pediatric Drug Designation to VCN-01 for Retinoblastoma

July 31st 2024

VCN-01 has received rare pediatric drug designation from the FDA for patients with retinoblastoma.

Pamrevlumab Fails to Provide OS Benefit in Pancreatic Cancer

July 31st 2024

Two late-stage trials investigating the efficacy and safety of pamrevlumab in pancreatic cancer failed to meet their primary end points of OS.

First-Line Avelumab Maintenance Extends OS in Advanced Urothelial Carcinoma With Low Tumor Burden

July 30th 2024

First-line avelumab maintenance demonstrated efficacy and manageable toxicity in patients with low tumor burden advanced urothelial carcinoma.

Liquid Biopsy in Oncology: Have We Just Scratched the Surface?

July 30th 2024

Circulating tumor cells and circulating extracellular vesicles should be integrated into liquid biopsy assays to improve their utility in oncology.

Uzzo Elucidates the Potential Role of KIM-1 as a Biomarker in RCC

July 30th 2024

Robert Uzzo, MD, details data from the IMmotion010 study on KIM-1 and how the biomarker could be used as well as future directions for investigating it in RCC.

ctDNA Carves a Precise Path for Early-Stage NSCLC Management

July 29th 2024

David R. Gandara, MD, discusses research reflecting the capabilities of ctDNA assays to detect MRD and prognosticate adjuvant NSCLC treatment outcomes.

Changes in HER2+ Breast Cancer May Include Tailored Therapy With pCR, Use of T-DXd

July 26th 2024

Adrienne G. Waks, MD, discusses the potential for pCR-guided treatment and highlights therapies for patients with residual disease beyond T-DM1.

ODAC Votes to Require Within Trial Assessment of Neoadjuvant vs Adjuvant Treatment Benefit in Perioperative Trial Protocols in Resectable NSCLC

July 25th 2024

Should the FDA require that new trial design proposals for perioperative regimens for resectable NSCLC include adequate within trial assessment?